MRSN Quote, Financials, Valuation and Earnings

Cue Biopharma, Inc. has a net margin of -68.54% compared to Mersana Therapeutics, Inc.'s net margin of -346.58%. Mersana Therapeutics, Inc.'s return on equity of -533.43% beat Cue Biopharma, Inc.'s return on equity of -233.04%.

Mersana Therapeutics, Inc. has a consensus price target of $33.20, signalling upside risk potential of 19.21%. On the other hand Cue Biopharma, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 804.16%. Given that Cue Biopharma, Inc. has higher upside potential than Mersana Therapeutics, Inc., analysts believe Cue Biopharma, Inc. is more attractive than Mersana Therapeutics, Inc..

Mersana Therapeutics, Inc. has a beta of 0.451, which suggesting that the stock is 54.856% less volatile than S&P 500. In comparison Cue Biopharma, Inc. has a beta of 1.393, suggesting its more volatile than the S&P 500 by 39.251%.

Mersana Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cue Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mersana Therapeutics, Inc. pays -- of its earnings as a dividend. Cue Biopharma, Inc. pays out -- of its earnings as a dividend.

Mersana Therapeutics, Inc. quarterly revenues are $11M, which are larger than Cue Biopharma, Inc. quarterly revenues of $2.1M. Mersana Therapeutics, Inc.'s net income of -$7.5M is lower than Cue Biopharma, Inc.'s net income of -$7.4M. Notably, Mersana Therapeutics, Inc.'s price-to-earnings ratio is -- while Cue Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mersana Therapeutics, Inc. is 54.14x versus 6.71x for Cue Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Day One Biopharmaceuticals, Inc. has a net margin of -68.54% compared to Mersana Therapeutics, Inc.'s net margin of -49.57%. Mersana Therapeutics, Inc.'s return on equity of -533.43% beat Day One Biopharmaceuticals, Inc.'s return on equity of -30.98%.

Mersana Therapeutics, Inc. has a consensus price target of $33.20, signalling upside risk potential of 19.21%. On the other hand Day One Biopharmaceuticals, Inc. has an analysts' consensus of $22.25 which suggests that it could grow by 166.79%. Given that Day One Biopharmaceuticals, Inc. has higher upside potential than Mersana Therapeutics, Inc., analysts believe Day One Biopharmaceuticals, Inc. is more attractive than Mersana Therapeutics, Inc..

Mersana Therapeutics, Inc. has a beta of 0.451, which suggesting that the stock is 54.856% less volatile than S&P 500. In comparison Day One Biopharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Mersana Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Day One Biopharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mersana Therapeutics, Inc. pays -- of its earnings as a dividend. Day One Biopharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Mersana Therapeutics, Inc. quarterly revenues are $11M, which are smaller than Day One Biopharmaceuticals, Inc. quarterly revenues of $39.8M. Mersana Therapeutics, Inc.'s net income of -$7.5M is higher than Day One Biopharmaceuticals, Inc.'s net income of -$19.7M. Notably, Mersana Therapeutics, Inc.'s price-to-earnings ratio is -- while Day One Biopharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mersana Therapeutics, Inc. is 54.14x versus 6.40x for Day One Biopharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Scholar Rock Holding Corp. has a net margin of -68.54% compared to Mersana Therapeutics, Inc.'s net margin of --. Mersana Therapeutics, Inc.'s return on equity of -533.43% beat Scholar Rock Holding Corp.'s return on equity of -142.69%.

Mersana Therapeutics, Inc. has a consensus price target of $33.20, signalling upside risk potential of 19.21%. On the other hand Scholar Rock Holding Corp. has an analysts' consensus of $47.33 which suggests that it could grow by 8.79%. Given that Mersana Therapeutics, Inc. has higher upside potential than Scholar Rock Holding Corp., analysts believe Mersana Therapeutics, Inc. is more attractive than Scholar Rock Holding Corp..

Mersana Therapeutics, Inc. has a beta of 0.451, which suggesting that the stock is 54.856% less volatile than S&P 500. In comparison Scholar Rock Holding Corp. has a beta of 0.608, suggesting its less volatile than the S&P 500 by 39.233%.

Mersana Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Scholar Rock Holding Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mersana Therapeutics, Inc. pays -- of its earnings as a dividend. Scholar Rock Holding Corp. pays out -- of its earnings as a dividend.

Mersana Therapeutics, Inc. quarterly revenues are $11M, which are larger than Scholar Rock Holding Corp. quarterly revenues of --. Mersana Therapeutics, Inc.'s net income of -$7.5M is higher than Scholar Rock Holding Corp.'s net income of -$102.2M. Notably, Mersana Therapeutics, Inc.'s price-to-earnings ratio is -- while Scholar Rock Holding Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mersana Therapeutics, Inc. is 54.14x versus 72.82x for Scholar Rock Holding Corp.. Usually stocks with elevated PS ratios are considered overvalued.